RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Homology Medicines Stock

Homology Medicines P/E 2024

Homology Medicines P/E

-1.34

Ticker

QTTB

ISIN

US4380831077

WKN

A2JGTY

As of Nov 20, 2024, Homology Medicines's P/E ratio was -1.34, a 0% change from the 0 P/E ratio recorded in the previous year.

The Homology Medicines P/E history

Homology Medicines Aktienanalyse

What does Homology Medicines do?

Homology Medicines Inc. is a US-based company focused on the development of gene therapy technologies. The company was founded in 2015 and is headquartered in Bedford, Massachusetts. Homology Medicines Inc. aims to develop and market innovative gene therapies for rare diseases and genetic disorders. The company's goal is to develop new therapies through gene editing that can specifically modify genes to treat or alleviate symptoms of diseases. Homology Medicines bases its methodology on the natural processes of viral transport, through which double-stranded DNA is anchored into the cell. This allows the DNA to be directly introduced into living tissue, where it has systemic effects. Homology's gene therapy technology is based on the recombination of adenoviral vectors. The business model of Homology Medicines is to develop and market innovative gene therapies for rare diseases and genetic disorders. The company focuses on close collaboration with clinics to make the new therapies quickly and efficiently available to patients. The company has a close partnership with the National Institute of Health (NIH) to utilize its technology for gene therapy of rare diseases and genetic disorders. Homology Medicines Inc. specializes in three different branches of gene therapy: 1. In vivo gene therapy: In this method, gene therapies are directly introduced into the patient's tissue. Homology Medicines is working on developing new efficient methods for virus transport of therapeutics into the central nervous system and cardiovascular tissue. These methods aim to minimize the occurrence of unwanted effects. 2. Ex vivo gene therapy: In ex vivo gene therapy, a patient's cells are taken, modified, and then reintroduced into the patient. This method is particularly relevant for immune system disorders and cancer treatments. Homology Medicines is working on new efficient methods for the transport of modifiers into cells. 3. Genome editing therapy: In this final branch, Homology Medicines is working on developing genome editors that are specifically designed for defective genes. The technology is intended for the treatment of genetic diseases and restoring the functionality of defective genes. Homology Medicines Inc. is known for its low costs in gene therapy development. By utilizing natural viral transport methods and closely analyzing defects in humans, the company is able to quickly and cost-effectively develop therapies for patients. The company has already initiated several successful developments in gene therapy and continues to seek new innovations and developments to better meet the needs of patients. Homology Medicines ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Homology Medicines's P/E Ratio

The Price to Earnings (P/E) Ratio of Homology Medicines is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Homology Medicines's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Homology Medicines is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Homology Medicines’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Homology Medicines stock

What is the price-to-earnings ratio of Homology Medicines?

The price-earnings ratio of Homology Medicines is currently -1.34.

How has the price-earnings ratio of Homology Medicines changed compared to last year?

The price-to-earnings ratio of Homology Medicines has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Homology Medicines high compared to other companies?

Yes, the price-to-earnings ratio of Homology Medicines is high compared to other companies.

How does an increase in the price-earnings ratio of Homology Medicines affect the company?

An increase in the price-earnings ratio of Homology Medicines would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Homology Medicines affect the company?

A decrease in the price-earnings ratio of Homology Medicines would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Homology Medicines?

Some factors that influence the price-earnings ratio of Homology Medicines are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Homology Medicines pay?

Over the past 12 months, Homology Medicines paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Homology Medicines is expected to pay a dividend of 0 USD.

What is the dividend yield of Homology Medicines?

The current dividend yield of Homology Medicines is .

When does Homology Medicines pay dividends?

Homology Medicines pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Homology Medicines?

Homology Medicines paid dividends every year for the past 0 years.

What is the dividend of Homology Medicines?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Homology Medicines located?

Homology Medicines is assigned to the 'Health' sector.

Wann musste ich die Aktien von Homology Medicines kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Homology Medicines from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Homology Medicines pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Homology Medicines in the year 2023?

In the year 2023, Homology Medicines distributed 0 USD as dividends.

In which currency does Homology Medicines pay out the dividend?

The dividends of Homology Medicines are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Homology Medicines

Our stock analysis for Homology Medicines Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Homology Medicines Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.